Physicians are "very satisfied" with Santarus' (SNTS +0.4%) Uceris a survey conducted by Stifel...

|By:, SA News Editor

Physicians are "very satisfied" with Santarus' (SNTS +0.4%) Uceris a survey conducted by Stifel Nicolaus (Buy, PT raised to $24 from $22) shows. Analyst Annabel Samimy also notes that gastroenterologists seem to be comfortable prescribing the drug for several off-label indications as well, supporting recent "anecdotal reports." SA contributor Oneil Trader thinks the shares have "room to more than double in the next couple of years."